CMPX - Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
Story updates
12:34:20 PM UTC
SquawkNews
Compass said the FDA recommended a trial demonstrating overall survival benefit before a BLA for tovecimig in previously treated biliary tract cancer.Material DetailsContext by AI AnalystThis shifts tovecimig from near-term filing hopes to additional confirmatory work, extending timelines. A clearl…
12:34:58 PM UTC
SquawkNews
Compass Therapeutics said the FDA recommended conducting a trial demonstrating a survival benefit before submitting a BLA for tovecimig in previously treated biliary tract cancer.Key Highlights:Original SEC Filing: Compass Therapeutics, Inc. [ CMPX ] - 8-K - Sep. 22, 2026This is an AI-powered summa…